Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry tracks Dupilumab's Real-World impact on COPD

NCT ID NCT07612878

Not yet recruiting Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This registry will follow 350 COPD patients starting dupilumab (Dupixent) to see how well it works and how safe it is in real life. Researchers will track flare-ups, lung function, and quality of life over 24 months, comparing them to similar patients not on the drug. The goal is to understand who benefits most from this treatment outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dupilumab (Dupixent)
What this could lead to
If successful, this could confirm that dupilumab helps reduce COPD flare-ups and improve breathing and quality of life in real-world settings.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. Dupilumab also has known side effects like injection reactions and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.